Zilia, a medical technology company specializing in the non-invasive assessment of ocular biomarkers, announced today a significant advancement in the deployment of its groundbreaking technology set to transform the diagnosis and management of ocular diseases.
Zilia’s innovative retinal camera, the Zilia Ocular FC, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), marking a pivotal moment in the company’s growth.
“Receiving this first FDA clearance for our retinal camera is not just a milestone, it’s a leap forward in our quest to safeguard the vision of millions,” said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. “We’re now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions.”
